Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection

J Antimicrob Chemother. 2021 Aug 12;76(9):2484-2485. doi: 10.1093/jac/dkab192.

Authors

A Bachelard¹, V Isernia¹, D Vallois¹, S Le Gac¹, L Chalal¹, R Landman^{1

2}, F Damond³, D Descamps^{2

3}, Y Yazdanpanah^{1

2}, G Peytavin^{2

4}, J Ghosn^{1

2}

Affiliations

¹ AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France.
² IAME-UMR 1137 INSERM, Université de Paris, Paris, France.
³ AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France.
⁴ AP-HP, Hospital Bichat-Claude Bernard, Pharmacology-Toxicology Laboratory, Paris, France.

PMID: 34109414
DOI: 10.1093/jac/dkab192

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Alanine
Amides
Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
Drug Combinations
Emtricitabine / therapeutic use
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring
Humans
Piperazines
Pyridones
Tenofovir / analogs & derivatives

Substances

Amides
Anti-HIV Agents
Anti-Retroviral Agents
Drug Combinations
Heterocyclic Compounds, 3-Ring
Piperazines
Pyridones
bictegravir
Tenofovir
tenofovir alafenamide
Emtricitabine
Alanine